Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shanghai Henlius Biotech's Enterprise Value for the quarter that ended in Dec. 2025 was €3,685.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shanghai Henlius Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €110.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Henlius Biotech EV-to-EBIT Related Terms
Shanghai Henlius Biotech EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2E8 vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Shanghai Henlius Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Henlius Biotech EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shanghai Henlius Biotech's EV-to-EBIT falls into.
Shanghai Henlius Biotech's current Enterprise Value is €4,417.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shanghai Henlius Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €110.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Henlius Biotech (FRA:2E8) has a EV-to-EBIT of 39.93 as of Aug. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shanghai Henlius Biotech and its competitors. According to the industry distribution chart, Shanghai Henlius Biotech ranks #280 out of 370 companies in the Biotechnology industry, placing it in the top 75.7%.
Is Shanghai Henlius Biotech's EV-to-EBIT too high?
Shanghai Henlius Biotech's current EV-to-EBIT is 39.93. The Biotechnology industry median EV-to-EBIT is 16.25. Shanghai Henlius Biotech's value of 39.93 is 145.8% above this industry median. Based on the distribution chart, Shanghai Henlius Biotech ranks #280 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Henlius Biotech has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Henlius Biotech's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Henlius Biotech ranks #280 out of 370 companies for EV-to-EBIT. This places Shanghai Henlius Biotech in the lower half of its industry. The industry median EV-to-EBIT is 16.25. Shanghai Henlius Biotech's value of 39.93 is 145.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.25, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Henlius Biotech's current EV-to-EBIT of 39.93 is 145.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shanghai Henlius Biotech and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Henlius Biotech's current EV-to-EBIT is 39.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Henlius Biotech stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Henlius Biotech (FRA:2E8) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.38, compared to a current price of €7.30 — trading 116% above its estimated fair value. The current EV-to-EBIT is 39.93 and 145.8% above the Biotechnology industry median of 16.25. Shanghai Henlius Biotech's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shanghai Henlius Biotech (FRA:2E8), the current EV-to-EBIT is 39.93 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Henlius Biotech (FRA:2E8) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued.
The current stock price of €7.30 is trading 116% above its estimated GF Value™ of €3.38.
GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.
Key valuation signals for FRA:2E8:
EV-to-EBIT: 39.93
GF Value™: €3.38 vs. price of €7.30 (116% above fair value)
Industry Position: 145.8% above the Biotechnology median (#280 of 370)
No single metric tells the full story. See the FRA:2E8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
50GF Score
Get the complete analysis for FRA:2E8
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E8 has been successfully added to your 
